People: NexMed, Inc. (NEXM.O)

NEXM.O on Consolidated Issue listed on NASDAQ Capital Market

0.48USD
11:09am EST
Price Change (% chg)

$-0.01 (-2.00%)
Prev Close
$0.49
Open
$0.48
Day's High
$0.51
Day's Low
$0.47
Volume
505,244
Avg. Vol
4,607,164
52-wk High
$0.84
52-wk Low
$0.08

view people for:

Summary

Name Age Since Current Position
Liu, Vivian 47 2009 Chairman of the Board, Executive Vice President
Damaj, Bassam 41 2009 President, Chief Executive Officer, Director
Westgate, Mark 39 2005 Chief Financial Officer, Vice President
Esber, Henry 71 2009 Executive Vice President - Pre-Clinical and Business Development, Director
Cox, Edward 2009 Vice President - Investor Relations & Corporate Development
Berman, Richard 67 2009 Director
Oppenheim, Leonard 62 2007 Director
Crea, Roberto 61 2009 Director
Ray, Rusty 39 2009 Director
» Insider Trading

Biographies

Name Description
Liu, Vivian Vivian H. Liu is Chairman of the Board, Executive Vice President of NexMed, Inc. He had been a director and President and Chief Executive Officer of since June 2007 and Secretary since 1995 of NexMed, Inc. Ms. Liu served as Vice President of Corporate Affairs from September 1995 until December 2005, Acting Chief Executive Officer from December 2005 until January 2006, Executive Vice President and Chief Operating Officer from January 2006 to June 2007, Chief Financial Officer from January 2004 until December 2005, Acting Chief Financial Officer from 1999 to January 2004 and Treasurer from September 1995 through December 2005. In 1994, while were in a transition period, Ms. Liu served as Chief Executive Officer. From 1985 to 1994, Ms. Liu was a business and investment adviser to the government of Quebec and numerous Canadian companies with respect to product distribution, technology transfer and investment issues. Ms. Liu received her MPA in International Finance from the University of Southern California and her BA from the University of California, Berkeley.
Damaj, Bassam Mr. Bassam B. Damaj serves as President, Chief Executive Officer, Director of NexMed Inc. He a co-founder of Bio-Quant, has served as the Chief Executive Officer and Chief Scientific Officer and a director of Bio-Quant since its inception in June 2000. He has also served as the Group Leader for the Office of New Target Intelligence and a Group Leader for immunological and inflammatory disease programs at Tanabe Research Laboratories, U.S.A., Inc., as a senior scientist and member of the senior staff board of the drug discovery department at Pharmacopeia Inc., and as a visiting scientist at Genentech Inc., Pfizer Inc. and the National Institutes of Health (NIAID). Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
Westgate, Mark Mark Westgate has been the Vice President, Chief Financial Officer of NexMed since December 2005. From March 2002 to December 2005, Mr. Westgate served as Controller. He has over fifteen years of public accounting and financial management experience. From August 1998 to March 2002, Mr. Westgate served as Controller and Director of Finance for Lavipharm Laboratories Inc, a company specializing in drug delivery and particle design. Prior to joining Lavipharm, he was a supervisor at Richard A. Eisner & Company, LLP where he performed audits and provided tax advice for clients in various industries including biotech. Mr. Westgate is a Certified Public Accountant and a member of the New York State Society of Certified Public Accountants. He holds a B.B.A. in public accounting from Pace University.
Esber, Henry Mr. Henry J. Esber serves as Executive Vice President - Pre-Clinical and Business Development, Director of NexMed Inc. He has served as the Senior Vice President and Chief Business Development Officer and a director of Bio-Quant since January 2006. From September 2000 to December 2005, Dr. Esber served as the executive director of business development at Charles River Laboratories, Inc., a global provider of research models and preclinical, clinical, and support services. Prior to that, Dr. Esber was an executive director at Primedica Corporation and Genzyme Transgenics Corporation, vice president at Bio-Development Laboratories, vice president at TSI Corporation, director at EG&G Mason Research Labs and the director of the Department of Immunology and Clinical Services at Mason Research Laboratories. Dr. Esber has also served as an affiliate professor at Anna Maria College Graduate School and the University of Connecticut. Dr. Esber holds a B.S. degree in Pre-Medicine from Norfolk College of William and Mary (now Old Dominion), a Master of Science degree in Public Health in Parasitology and Public Health from the University of North Carolina, Chapel hill and a Ph.D. degree in Immunology/Microbiology from West Virginia University Medical Center, Morgantown.
Cox, Edward Edward Cox was named Vice President Investor Relations & Corporate Development of Nexmed, Inc. in December 2009, having previously served as President and a member of the Board of Directors of Bio-Quant since January 2007. He has extensive experience in finance and strategic business planning for pre-IPO companies. Mr. Cox has served as an Officer and/or Director of several early-stage and publicly traded companies including TomCo Energy (TOM:L) and Pangea Pictures Corporation. He also acted as a Business Strategist and Consultant for several companies such as Tequesta Marine Biosciences. Mr. Cox holds a Masters of Science in Business from the University of Florida.
Berman, Richard Richard J. Berman is a Director of NexMed, Inc. Mr. Berman served as the Board's non-executive Chairman from June 2007-December 2009, having served as C.E.O. of the Company from January 2006-June 2007, and on the Board of Directors since 2002. He also served as a member of the Audit Committee, Executive Compensation Committee, and Corporate Governance/Nominating Committee of the Board of Directors between June 2002 and January 2006. Mr. Berman currently serves as Chairman of National Investment Managers, a public company in pension administration and investment management (OTC: NIVM.OB); Chairman of Fortress Technology Systems (homeland security), and Chairman of Morlex, Inc. (internet) (OTC: MORX.OB). Mr. Berman is a director of eight public companies: NexMed, Inc., Morlex, Inc., National Investment Managers, Broadcaster, Inc. (OTC: BCSR.OB), Easylink Services International, Inc. (Nasdaq: ESIC), (OTC: NIVM.OB), Advaxis, Inc. (OTC: ADXS.OB), NeoStem, Inc (ASE: NBS), and Fortress Technology Systems (listed on the Frankfurt Exchange). From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services International, Inc.) as Chairman and CEO. Previously, Mr. Berman worked at Goldman Sachs; was Senior Vice President of Bankers Trust Company, where he started the M&A and Leveraged Buyout Departments; created the largest battery company in the world by merging Prestolite, General Battery and Exide to form Exide Technologies (NASDAQ: XIDE); helped create what is now Soho (NYC) by developing five buildings; and advised on over $4 billion of M&A transactions. He is a past Director of the Stern School of Business of NYU where he obtained his BS and MBA. He also has U.S. and foreign law degrees from Boston College and The Hague Academy of International Law, respectively.
Oppenheim, Leonard Leonard A. Oppenheim has been a director since 2004, and a member of the Audit Committee since January 2006 and Finance Committee since June 2006. Mr. Oppenheim served as the Chairman of the Board from June 2006 through June 18, 2007. His current term as a member of the Board of Directors expires in 2008, and if re-elected at the Annual Meeting, in 2011. Mr. Oppenheim retired from business in 2001 and has since been active as a private investor. From 1999 to 2001, Mr. Oppenheim was a partner in Faxon Research, a company offering independent research to professional investors. From 1983 to 1999, Mr. Oppenheim was a principal in the Investment Banking and Institutional Sales division of Montgomery Securities. Prior to that, he was a practicing attorney. Mr. Oppenheim graduated from New York University Law School in 1976.
Crea, Roberto Dr. Roberto Crea serves as Director of NexMed Inc. He has been a director of Bio-Quant since November 2008. Dr. Crea has over 30 years of experience in the biotechnology field as a scientist, investor and entrepreneur. Since October 2005, he has served as the President and Chief Executive Officer of ProtElix, Inc., a privately held, early stage biotherapeutic company focused on the discovery and development of optimized protein therapeutics. Prior to that, from January 2002 to August 2005, Dr. Crea served as a founder and the Chief Executive Officer of Bioren, Inc., which was acquired by Pfizer, Inc. in August 2005. He is also one of the scientific co-founders of Genentech, Inc., and founder of Creative Bio Molecules, Inc. (1982), Creagen, Inc. (1992) and CreAgri, Inc. (1998). Dr. Crea holds a Ph.D. degree in Biological Chemistry from University of Pavia, Italy. He was also an Associate Professor of DNA Chemical Synthesis at Leiden University in the Netherlands prior to moving to the United States in 1977. Dr. Crea currently serves as a director of CreAgri, Inc., ProtElix, Inc. and SynGen, Inc.
Ray, Rusty Mr. Rusty Ray serves as Director of NexMed Inc. He is currently a partner with Brocair Partners, a healthcare focused investment bank, and has been with Brocair Partners since its founding in 2004. Since joining Brocair, he has worked with a wide variety of clients across the healthcare industry ranging from large pharmaceutical companies to early-stage drug development companies to medical device and service-based companies. Prior to joining Brocair Partners, Mr. Ray was a Deputy Director for eight years with Resources for the Future (RFF) a non-partisan Washington-based think tank that conducts independent economic research. During his tenure at RFF, the organization conducted a number of studies related to the pharmaceutical and biotechnology industries. Beyond life sciences, Mr. Ray also worked on issues related to emissions credit trading and utility restructuring. Prior to joining RFF, Mr. Ray worked with The Meningitis Research Foundation in London where he worked to support basic research to cure the disease. Mr. Ray is currently a Director of New Media Mill, a digital media company. Mr. Ray holds an M.B.A. in Finance from the Fordham University School of Business, and received a B.S. in Biology from Wake Forest University.

Basic Compensation

Name Fiscal Year Total
Liu, Vivian 991,595
Damaj, Bassam --
Westgate, Mark 289,874
Esber, Henry --
Cox, Edward --
Berman, Richard 162,840
Oppenheim, Leonard --
Crea, Roberto --
Ray, Rusty --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Liu, Vivian 674,284 113,992
Damaj, Bassam 0 0
Westgate, Mark 122,273 6,000
Esber, Henry 0 0
Cox, Edward 0 0
Berman, Richard 0 0
Oppenheim, Leonard 0 0
Crea, Roberto 0 0
Ray, Rusty 0 0

Insider Trading

Name Shares Traded Price
ESBER HENRY JEMIL 234,753 $0.17
DAMAJ BASSAM B 204,657 $0.17
CREA ROBERTO 10,233 $0.17
DAMAJ BASSAM B 485,443 $0.17
ESBER HENRY JEMIL 120,386 $0.17
COX EDWARD M 52,819 $0.17
OPPENHEIM LEONARD A 150,707 $0.42
EMIL ARTHUR D 10,708 $1.47
WADE MARTIN R III 10,708 $1.47
OPPENHEIM LEONARD A 10,708 $1.47
TIERNEY DAVID S 10,708 $1.47
BERMAN RICHARD J 20,541 $1.47
PANDYA HEMANSHU N 10,000 $0.20
PANDYA HEMANSHU N 210,000 $0.21
PANDYA HEMANSHU N 5,000 $0.20
PANDYA HEMANSHU N 10,000 $0.20
PANDYA HEMANSHU N 20,000 $0.21
PANDYA HEMANSHU N 20,000 $0.21
PANDYA HEMANSHU N 10,000 $0.21
PANDYA HEMANSHU N 20,000 $0.21
PANDYA HEMANSHU N 20,000 $0.20
MAY JACOB 2,620,900 $0.24
MAY JACOB 1,500,000 $0.17
OPPENHEIM LEONARD A 10,708 $1.47
EMIL ARTHUR D 10,708 $1.47
» Full list on Insider Trading
view people for: